Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.1500+0.0800 (+1.97%)
At close: 04:00PM EDT
4.0900 -0.06 (-1.45%)
After hours: 06:16PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • a
    angela
    It’s just amazing to me that the last print in the aftermarket shows down .18 cents to $4.17…if you look that’s 1 share that traded to make that print .just another game that’s played to scare investors…let the earnings tell the story…good luck tomorrow…
  • G
    G
    Earnings will get better every quarter. This company has 10-15 years of growth ahead of it. I’m heavily invested and very excited about this company.
    Bullish
  • S
    ST
    Lqda up 22%……..
  • r
    robert
    Let’s face it that with UTHR’s money rolling in very soon (was not accounted for in Q2’s revenue, this company should be profitable my Q4 this year. Comments?
  • r
    robert
    Patent to be invalidated so that is why LQDA is up 20%! Mnkd going nowhere.
  • C
    Ch
    lqda almost @ 6
  • B
    BuyMNKD
    Numerous catalysts to cause stock price to rise for #MNKD :
    🥭 MannKind has enough capital to operate for several years & fund pipeline
     🥭 Afrezza cash flow break even in 2023
     🥭 Afrezza Phase 3 India clinical trial ongoing
     🥭 Afrezza Pediatric Phase 3 clinical trial readout late 2023, >ahead of enrollment schedule
     🥭 New Afrezza Phase 4 clinical trial this year
     🥭 Tyvaso DPI approved and launched
     🥭 >$100 MILLION in annual Tyvaso DPI royalties + manufacturing royalties
     🥭 Clofazimine Phase 1 ongoing; Ph 2 in Dec.
     🥭 Nintedanib for IPF advancing
     🥭 Dornase Alpha for cystic fibrosis
     🥭 TGF-B for IPF advancing
     🥭 Additional indications for Tyvaso DPI + years of exclusivity and zero competition PH-COPD, PH-ILD, IPF
     🥭 No serious adverse events & No bronchospasm in Tyvaso DPI clinical trials
     🥭 Launching 1 new product or indication beginning 2025
     🥭 TGF-B pharmacodynamics study results 2H this year
     🥭 >1,200 Afrezza patents in force world wide and growing
    🥭 Immediate added Revenue stream with acquisition of V-Go insulin pump
    Bullish
  • a
    angela
    Looking for a great earnings report next week to shake out the short position…no more lies from the make believe short sellers. Let the numbers spell out the truth about how well this company is doing…
  • B
    BuyMNKD
    Here are the Tyvaso reasons to buy MNKD:
    •MNKD manufacturing facilty inspection passed ✔
    •Tyvaso DPI mfg cost reimbursements flowing to MNKD ✔
    •BREEZE study proved Tyvaso DPI safe ✔
    •Tyvaso DPI FDA approved for PH + PHILD with clean label ✔
    •Tyvaso DPI royalty $ flowing to MNKD ✔
    •Additional refrigerated storage facility buildout ✔
         More reasons to come:
    •Additional maufacturing line buildout  [ '22 ]
    •Tyvaso DPI NDA to be filed for PH-COPD [ '22 ]
    •Tyvaso DPI NDA to be filed for PH-IPF [ '23 ]
    Bullish
  • C
    Ch
    shaking out weak hands 😀
  • C
    Ch
    shorts need still to buy 22million shares. big break out on the way 😀
  • S
    Stotts
    Just heard that MNKD got alerted at (http://market-engross.club). I hope it pushes us higher!
  • B
    BuyMNKD
    #MNKD will run up to & thru #UTHR's earnings release on Wednesday and continue up to & thru its own earnings release next week. Hold onto them shares!
    Bullish
  • r
    robert
    @Avi8tor: what say you now with earnings report?
  • G
    Giants
    “Tyvaso DPI is MannKind's second marketed drug, so it will be interesting to see how well it does in the marketplace. For now, it is the only approved dry-powder inhaled treatment for PAH patients with PH-ILD. The company lost $26 million, or $0.10 per share, in the first quarter. But its revenue for its other approved drug, Afrezza, a man-made form of inhaled insulin, was $9.8 million, up 21% over the same period last year. With a second drug on the market, the company may be about to turn the corner to profitability.”
  • S
    Sach
    Uhhh…swerve, you’d best start using another of your aliases.
  • C
    Ch
    great close again. tomorrow 4.50 +
  • C
    Ch
    lets close to 4.40 4.47 :)
  • n
    nomdguer
    The timing of Swerve’s sale of all of his MNKD stock two weeks ago was perfect. Well done!
  • C
    Ch
    Last chance to buy under 5 today 😀 😀
Advertisement
Advertisement